6 recruiting, 3 completed, 3 not yet recruiting, 3 unknown. 19 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Recruiting 6, Completed 3, Not yet recruiting 3, Unknown 3, Active not recruiting 2, Terminated 2 |
| Phase 2 | 5 | Not yet recruiting 2, Recruiting 2, Completed 1 |
Follow T-cell Acute Lymphoblastic Leukemia: new trials by email Literature Review of T-cell Acute Lymphoblastic Leukemia trials Research Report on T-cell Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-11-02 |
| A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Autologous nano CD5-CAR T Cells - T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2026-06-30 | 2026-07-01 |
| Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma Venetoclax, Dexamethasone, Bortezomib - T-cell Acute Lymphoblastic Leukemia, Lymphoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 18 | 2026-06-05 | 2026-08-12 |
| NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL Antigen-specific T cells CAR-T/CTL and DCvac - T-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2026-06-01 | 2026-11-03 |
| Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells CD7.CAR/28zeta T Cells - T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-05-12 | 2026-05-18 |
| Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells CD5/CD7 CAR-T - T Cell Lymphoma, T Cell Leukemia | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2024-07-10 | 2024-11-12 |
| Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell - T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 80 | 2024-03-22 | 2025-11-26 |
| Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma Daratumumab - T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma | Phase 1 | Recruiting | New York Medical College | 30 | 2023-05-22 | 2026-09-11 |
| Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL CD1a-CAR T - T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma | Phase 1 | Recruiting | OneChain Immunotherapeutics | 20 | 2023-01-31 | 2026-03-11 |
| CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia CD5 CAR-T - T-cell Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Xuanwu Hospital, Beijing | 20 | 2022-10-25 | 2022-10-27 |
| Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies anti-CD7 CAR-T cells - T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia | Phase 1 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 14 | 2022-05-04 | 2025-06-06 |
| A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL WU-CART-007 - T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 1 | Completed | Allotera Therapeutics | 28 | 2022-01-14 | 2025-09-30 |
| Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia CD5 CART - T-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Beijing Boren Hospital | 19 | 2021-09-14 | 2024-11-14 |
| Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells CD7.CAR/28zeta CAR T cells - T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 45 | 2021-08-02 | 2026-10-02 |
| Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances CD7 CAR T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2020-12-01 | 2021-06-22 |
| Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies anti-CD5 CAR T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma | Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2020-12-01 | 2021-03-02 |
| Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells - T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 104 | 2017-11-01 | 2026-11-04 |
| A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL LY3039478, Dexamethasone, Placebo - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 36 | 2015-10-01 | 2019-09-11 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (19) · Lymphoma (4) · Lymphoma, T-Cell (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Leukemia, T-Cell (2) · Hematologic Neoplasms (1) · Immunoblastic Lymphadenopathy (1) · Leukemia, Prolymphocytic, T-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell, Peripheral (1)
Hematologic Diseases (19) · Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Leukemia, Lymphoid (19) · Lymphatic Diseases (19) · Lymphoproliferative Disorders (19) · Neoplasms (19) · Neoplasms by Histologic Type (19) · Leukemia (17) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (16) · Lymphoma, Non-Hodgkin (4) · Leukemia, Myeloid (2) · Leukemia, Prolymphocytic (1) · Lymphadenopathy (1)
Dexamethasone (2) · daratumumab (2) · Bortezomib (1) · S-1,2-dichlorovinyl-N-acetylcysteine (1) · crenigacestat (1) · venetoclax (1)
Baylor College of Medicine (3) · Shenzhen Geno-Immune Medical Institute (3) · iCell Gene Therapeutics (2) · Allotera Therapeutics (1) · Beijing Boren Hospital (1) · Beijing GoBroad Hospital (1) · Eli Lilly and Company (1) · Essen Biotech (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · M.D. Anderson Cancer Center (1) · New York Medical College (1) · OneChain Immunotherapeutics (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Xuanwu Hospital, Beijing (1)
China (10) · United States (7) · France (2) · Australia (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Spain (1)
Rayne Rouce, MD (3) · LaQuisa Hill, MD (2) · Allyson Flower, MD (1) · Cherry Thomas, MD (1) · Hongyu Zhang (1) · Hongyu Zhang, MD/PhD (1) · Huyong Zheng, MD, PhD (1) · Jing Pan, Master (1) · Miriam B Garcia, DOp (1) · Mitchell Cairo, MD (1) · Troy Quigg, DO (1) · Xianmin G Song, M.D. (1) · Zhiguo Chen, PhD (1)
PMID 33107983, PMID 34274536, PMID 36086817, PMID 36858787, PMID 39149468, PMID 39354195, PMID 40445850
2014 (1), P50CA126752 (1), R35CA210084 (1)